Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus.

OBJECTIVE To establish and validate a double-antibody radioimmunoassay (RIA) for detecting serum auto-antibodies against glutamic acid decarboxylase (GAD65). This enzyme catalyzes synthesis of the neurotransmitter gamma-aminobutyric acid in neurons and pancreatic islet cells. MATERIAL AND METHODS We compared the frequency of GAD65 and other "thyrogastric" autoantibodies in adult patients with stiff-man (Moersch-Woltman) syndrome, type 1 diabetes, or polyendocrine disorders and in healthy subjects. The frequency of pancreatic islet cell antibody (ICA) detection was also assessed. The GAD65 RIA was validated by testing blinded samples, by confirming the specificity of low-titered positive results by "cold" antigen inhibition, and by comparing the RIA results with results of a kit assay incorporating staphylococcal protein A as immunoprecipitant. Recombinant GAD65 protein labeled with 125I was used as antigen, and a combination of anti-human IgG and IgM was used as immunoprecipitant. Seropositivity was determined for ICA and gastric parietal cell antibodies by indirect immunofluorescence assays and for thyroid peroxidase (microsome) and thyroglobulin antibodies by agglutination assays. RESULTS We detected GAD65-specific antibodies in all but 1 of 46 local patients with stiff-man syndrome (98%); 16 had evidence of diabetes. Positive values exceeded 20 nmol/L in 96%, and 89% were ICA-positive; 76% had additional thyrogastric antibodies. Of 41 patients with type 1 diabetes (17 local and 24 workshop serum specimens), 33 were GAD65 antibody-positive (80%); 85% of these positive values were 20 nmol/L or lower. Only 18% of sera from patients with type 1 diabetes were ICA-positive, but 59% had other thyrogastric autoantibodies. Of 20 patients with autoimmune endocrinopathies without diabetes or stiff-man syndrome, 35% were GAD65 antibody-positive, 5% were ICA-positive, and 90% were thyrogastric antibody-positive. Of 117 healthy control subjects, 8% were GAD65 antibody-positive, and a third of those had other thyrogastric antibodies (14% overall); none was ICA-positive. CONCLUSION Seropositivity in the double-antibody RIA for GAD65 autoantibody is a sensitive and specific marker of predisposition to type 1 diabetes and related organ-specific autoimmune disorders. As such, this RIA is complemented by assays for thyroid and gastric parietal cell autoantibodies.

[1]  V. Lennon,et al.  Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes , 1998, Neurology.

[2]  P. O'Suilleabhain,et al.  Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome , 1998, Neurology.

[3]  E. Tolosa,et al.  Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity , 1997, Neurology.

[4]  R. Volpe.  The Autoimmune Endocrinopathies The Complexities Continue to Ravel , 1997, Trends in Endocrinology & Metabolism.

[5]  N. Itoh,et al.  Radioimmunoprecipitation assay for glutamic acid decarboxylase antibodies evaluated clinically with sera from patients with insulin-dependent diabetes mellitus. , 1996, Clinical chemistry.

[6]  H. Chase,et al.  Prediction of Type I Diabetes in First-Degree Relatives Using a Combination of Insulin, GAD, and ICA512bdc/IA-2 Autoantibodies , 1996, Diabetes.

[7]  M. Atkinson,et al.  Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. , 1996, Journal of immunology.

[8]  E. Bonifacio,et al.  Disease Sensitivity and Specificity of 52 Assays for Glutamic Acid Decarboxylase Antibodies: The Second International GADAB Workshop , 1995, Diabetes.

[9]  S. Baekkeskov,et al.  Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus , 1994, The Journal of experimental medicine.

[10]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[11]  L. Velloso,et al.  GAD Autoantibodies in IDDM, Stiff-Man Syndrome, and Autoimmune Polyendocrine Syndrome Type I Recognize Different Epitopes , 1994, Diabetes.

[12]  A. Tobin,et al.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes , 1993, Nature.

[13]  R. Tisch,et al.  Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice , 1993, Nature.

[14]  L. Groop,et al.  Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.

[15]  O. Madsen,et al.  Recombinant Glutamic Acid Decarboxylase (Representing the Single Isoform Expressed in Human Islets) Detects IDDM-Associated 64,000-Mr Autoantibodies , 1992, Diabetes.

[16]  M. Rowley,et al.  Antibodies to Glutamic Acid Decarboxylase Discriminate Major Types of Diabetes Mellitus , 1992, Diabetes.

[17]  P. Camilli,et al.  Autoimmunity to glutamic acid decarboxylase (GAD) in stiffman syndrome and insulin-dependent diabetes mellitus , 1991, Trends in Neurosciences.

[18]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[19]  F. Howard,et al.  Stiff-man syndrome updated. , 1989, Mayo Clinic proceedings.

[20]  P. De Camilli,et al.  Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. , 1988, The New England journal of medicine.

[21]  C. de Beaufort,et al.  Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. , 1987, The Journal of clinical investigation.

[22]  J. Palmer,et al.  Insulin antibodies in insulin-dependent diabetics before insulin treatment. , 1983, Science.

[23]  S. Baekkeskov,et al.  Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins , 1982, Nature.

[24]  D. Doniach,et al.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. , 1974, Lancet.

[25]  V. Lennon,et al.  Immunopharmacological disease: a break in tolerance to receptor sites. , 1971, Lancet.

[26]  Graham-Stewart Cw.  TERMINATION OF PREGNANCY ON PSYCHIATRIC GROUNDS. , 1964 .

[27]  H. W. Woltman,et al.  Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases. , 1956, Proceedings of the staff meetings. Mayo Clinic.

[28]  W. A. Hudson,et al.  Letter: Oxprenolol and psoriasis-like eruption. , 1975, Lancet.

[29]  P. Gell,et al.  Clinical aspects of immunology , 1968 .